Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
Abstract Background Neoadjuvant chemotherapy with dual-targeted therapy is the standard treatment for human epidermal growth factor 2 (HER2)-positive breast cancer. Although the dual-targeted therapy has significantly improved the pathological complete response (pCR) rate, further investigation is n...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-11871-0 |
| _version_ | 1797276496926081024 |
|---|---|
| author | Zheng-Jun Yang Fei Xin Zu-Jin Chen Yue Yu Xin Wang Xu-Chen Cao |
| author_facet | Zheng-Jun Yang Fei Xin Zu-Jin Chen Yue Yu Xin Wang Xu-Chen Cao |
| author_sort | Zheng-Jun Yang |
| collection | DOAJ |
| description | Abstract Background Neoadjuvant chemotherapy with dual-targeted therapy is the standard treatment for human epidermal growth factor 2 (HER2)-positive breast cancer. Although the dual-targeted therapy has significantly improved the pathological complete response (pCR) rate, further investigation is needed to identify biomarkers that predict the response to neoadjuvant therapy. Methods This retrospective study analyzed 353 patients with HER2-positive breast invasive ductal carcinoma. The correlation between clinicopathological factors and pCR rate was evaluated. A nomogram was constructed based on the results of the multivariate logistic regression analysis to predict the probability of pCR. Results The breast pCR (b-pCR) rate was 56.1% (198/353) and the total pCR (t-pCR) rate was 52.7% (186/353). Multivariate analysis identified ER status, PR status, HER2 status, Ki-67 index, and neoadjuvant chemotherapy regimens as independent indicators for both b-pCR and t-pCR. The nomogram had an area under the receiver operating characteristic curve (AUC) of 0.73 (95% CI: 0.68–0.78). According to the nomogram, the t- pCR rate was highest in the ER-PR- HER2-positive patients (131/208) and lowest in the ER + PR + HER2-positive patients (19/73). The subgroup analyses showed that there was no significant difference in pCR rate among the neoadjuvant chemotherapy regimens in ER positive, PR positive, HER2 IHC 2 + , Ki67 index < 30% population. However, for ER-PR-HER2-positive patients, the neoadjuvant chemotherapy regimen has a great influence on the pCR rates. Conclusions Patients with ER-negative, PR-negative, HER2 3 + and high KI-67 index were more likely to achieve pCR. THP may be used as an alternative to AC-THP or TCbHP in selected HER2-positive patients. |
| first_indexed | 2024-03-07T15:29:01Z |
| format | Article |
| id | doaj.art-b9a53d4423e0479298031e15d60fc02d |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-07T15:29:01Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-b9a53d4423e0479298031e15d60fc02d2024-03-05T16:32:44ZengBMCBMC Cancer1471-24072024-01-0124111010.1186/s12885-024-11871-0Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancerZheng-Jun Yang0Fei Xin1Zu-Jin Chen2Yue Yu3Xin Wang4Xu-Chen Cao5The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerThe First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerThe First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerThe First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerThe First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerThe First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerAbstract Background Neoadjuvant chemotherapy with dual-targeted therapy is the standard treatment for human epidermal growth factor 2 (HER2)-positive breast cancer. Although the dual-targeted therapy has significantly improved the pathological complete response (pCR) rate, further investigation is needed to identify biomarkers that predict the response to neoadjuvant therapy. Methods This retrospective study analyzed 353 patients with HER2-positive breast invasive ductal carcinoma. The correlation between clinicopathological factors and pCR rate was evaluated. A nomogram was constructed based on the results of the multivariate logistic regression analysis to predict the probability of pCR. Results The breast pCR (b-pCR) rate was 56.1% (198/353) and the total pCR (t-pCR) rate was 52.7% (186/353). Multivariate analysis identified ER status, PR status, HER2 status, Ki-67 index, and neoadjuvant chemotherapy regimens as independent indicators for both b-pCR and t-pCR. The nomogram had an area under the receiver operating characteristic curve (AUC) of 0.73 (95% CI: 0.68–0.78). According to the nomogram, the t- pCR rate was highest in the ER-PR- HER2-positive patients (131/208) and lowest in the ER + PR + HER2-positive patients (19/73). The subgroup analyses showed that there was no significant difference in pCR rate among the neoadjuvant chemotherapy regimens in ER positive, PR positive, HER2 IHC 2 + , Ki67 index < 30% population. However, for ER-PR-HER2-positive patients, the neoadjuvant chemotherapy regimen has a great influence on the pCR rates. Conclusions Patients with ER-negative, PR-negative, HER2 3 + and high KI-67 index were more likely to achieve pCR. THP may be used as an alternative to AC-THP or TCbHP in selected HER2-positive patients.https://doi.org/10.1186/s12885-024-11871-0HER2 positiveBreast cancerNeoadjuvant chemotherapyDual-targeted therapy |
| spellingShingle | Zheng-Jun Yang Fei Xin Zu-Jin Chen Yue Yu Xin Wang Xu-Chen Cao Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer BMC Cancer HER2 positive Breast cancer Neoadjuvant chemotherapy Dual-targeted therapy |
| title | Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer |
| title_full | Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer |
| title_fullStr | Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer |
| title_full_unstemmed | Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer |
| title_short | Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer |
| title_sort | real world data on neoadjuvant chemotherapy with dual anti her2 therapy in her2 positive breast cancer |
| topic | HER2 positive Breast cancer Neoadjuvant chemotherapy Dual-targeted therapy |
| url | https://doi.org/10.1186/s12885-024-11871-0 |
| work_keys_str_mv | AT zhengjunyang realworlddataonneoadjuvantchemotherapywithdualantiher2therapyinher2positivebreastcancer AT feixin realworlddataonneoadjuvantchemotherapywithdualantiher2therapyinher2positivebreastcancer AT zujinchen realworlddataonneoadjuvantchemotherapywithdualantiher2therapyinher2positivebreastcancer AT yueyu realworlddataonneoadjuvantchemotherapywithdualantiher2therapyinher2positivebreastcancer AT xinwang realworlddataonneoadjuvantchemotherapywithdualantiher2therapyinher2positivebreastcancer AT xuchencao realworlddataonneoadjuvantchemotherapywithdualantiher2therapyinher2positivebreastcancer |